Inhibitor Therapeutics(INTI)
$0.080.00 (0.00%)
INTI
Inhibitor Therapeutics financials statements
$0.08
At close:0.00 (0.00%)
Inhibitor Therapeutics (INTI) Income Statement
32 Followers
Inhibitor Therapeutics Income Statement
Last quarter (Q2 2026), Inhibitor Therapeutics's total revenue was $0.00. In Q2, Inhibitor Therapeutics's net income was $-613.93K. See Inhibitor Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 3.43M | $ 3.66M | $ 3.40M | $ 657.93K | $ 325.39K | |
| Depreciation and Amortization | $ 0.00 | $ 3.66M | $ 3.40M | $ 657.93K | $ 325.39K |
| $ -3.43M | $ 318.41K | $ 378.98K | $ -74.00 | $ -130.60K | |
| $ -3.43M | $ -3.66M | $ -3.40M | $ -658.00K | $ -325.00K | |
| $ 126.32K | $ 318.21K | $ 378.84K | $ 12.82M | $ 26.76K | |
| $ -3.30M | $ -3.34M | $ -3.03M | $ 12.16M | $ -299.00K | |
| $ -3.30M | $ -3.34M | $ -3.03M | $ 12.11M | $ -299.00K | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.02 | $ -0.02 | $ -0.02 | $ 0.03 | $ -0.00 |
| Diluted EPS | $ -0.02 | $ -0.02 | $ -0.02 | $ 0.03 | $ -0.00 |
| Weighted Average Shares Outstanding | 172.51M | 172.26M | 151.31M | 366.18M | 376.25M |
| Weighted Average Shares Outstanding (Diluted) | 172.51M | 172.26M | 171.95M | 367.78M | 376.25M |
Currency in USD
